X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Under the agreement, GSK has the rights to develop GSK5458448/SCY-078 (ibrexafungerp), a novel oral glucan synthase inhibitor with a broad spectrum of activity and commercialize Brexafemme (ibrexafungerp tablets) in all countries except the greater China region.
Lead Product(s): Ibrexafungerp Citrate,Caspofungin
Therapeutic Area: Infections and Infectious Diseases Product Name: GSK5458448
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $401.0 million Upfront Cash: $90.0 million
Deal Type: Licensing Agreement January 03, 2024
Details:
Brexafemme (ibrexafungerp), a novel glucan synthase inhibitor, approved for vulvovaginal candidiasis and RVVC, is being develop in phase 3 trials for the potential treatment of invasive candidiasis.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hansoh Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Details:
Under the agreement GSK gains right to commercialize Brexafemme (ibrexafungerp), a novel glucan synthase inhibitor, for vulvovaginal candidiasis and RVVC while continuing to develop ibrexafungerp, in phase 3 trials for the potential treatment of invasive candidiasis.
Lead Product(s): Ibrexafungerp Citrate,Caspofungin
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $593.0 million Upfront Cash: $90.0 million
Deal Type: Licensing Agreement June 21, 2023
Details:
Under the agreement, GSK has the rights to develop ibrexafungerp, a novel oral glucan synthase inhibitor with a broad spectrum of activity and commercialize Brexafemme (ibrexafungerp tablets) in all countries except the greater China region.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $593.0 million Upfront Cash: $90.0 million
Deal Type: Licensing Agreement May 12, 2023
Details:
Under the agreement, GSK gains rights to commercialise Brexafemme, a first-in-class antifungal for the treatment of VVC and for reduction in the incidence of RVVC while continuing to develop ibrexafungerp, which is in phase III trials for the potential treatment of IC.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 30, 2023
Details:
Brexafemme (ibrexafungerp) is a novel oral triterpenoid antifungal approved for the treatment of vulvovaginal candidiasis (VVC). Its mechanism of action, glucan synthase inhibition, is fungicidal against Candida species, meaning it kills fungal cells.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
Brexafemme (Ibrexafungerp) is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
Cumulative interim analysis of outcomes by fungal disease type highlighted in a platform presentation demonstrates 82.3% positive clinical outcomes in patients treated with brexafemme (ibrexafungerp).
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
Brexafemme (ibrexafungerp) is in late-stage development for multiple indications, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species in hospitalized patients.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
71% of refractory vulvovaginal candidiasis cases treated with brexafemme (ibrexafungerp) showed clinical improvement as determined by vulvovaginal signs and symptoms score ≤1 at test of cure, 7% had stable response, 14% showed disease progression, and 7% were indeterminate.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
Brexafemme (Ibrexafungerp also formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
The CANDLE study met its primary endpoint, with 65.4% of patients with recurrent vulvovaginal candidiasis who received monthly single-day ibrexafungerp treatment achieving clinical success with no recurrence at all, either culture-proven, presumed or suspected.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Details:
Regulatory submission for the label extension is supported by positive data from the pivotal Phase 3 CANDLE study in which Brexafemme (ibrexafungerp) successfully achieved statistically significant superiority over placebo for the primary and key secondary study endpoints.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
Data show that 71% of 24 patients with recurrent vulvovaginal candidiasis failed to respond to three-day regimen of fluconazole achieved a substantial reduction or complete elimination of signs and symptoms after receiving one-day treatment with Brexafemme (ibrexafungerp).
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022
Details:
Brexafemme (ibrexafungerp citrate) is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2022
Details:
Brexafemme (ibrexafungerp) is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2022
Details:
Regulatory submission for label extension is supported by positive data from the pivotal Phase 3 CANDLE study in which Brexafemme (ibrexafungerp tablets) ) successfully achieved statistically significant superiority over placebo for primary and key secondary study endpoints.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
Brexafemme (Ibrexafungerp) demonstrated positive results in difficult-to-treat VVC patients with severe fungal infections who were either intolerant to standard antifungal therapy or experienced refractory infections despite treatment.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2022
Details:
Brexafemme (ibrexafungerp), is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
New interim analysis of the Phase 3 CARES study showed complete or partial response in 78% of the 18 patients treated with ibrexafungerp for infections caused by Candida auris, a potentially deadly and multidrug-resistent pathogen.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
Data reinforce findings from previous analyses demonstrating oral ibrexafungerp, structurally-distinct glucan synthase inhibitors potential to combat difficult-to-treat and refractory fungal infections in the hospital setting.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2022
Details:
Brexafemme, is an antifungal agent structurally-distinct glucan synthase inhibitors, triterpenoids. This agent combines well-established activity of glucan synthase inhibitors with potential flexibility of having oral and intravenous formulations.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
BREXAFEMME (ibrexafungerp tablets), is a novel oral antifungal approved for treatment of vulvovaginal candidiasis, also known as vaginal yeast infection. Its mechanism of action, glucan synthase inhibition, is fungicidal against Candida species, meaning it kills fungal cells.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
Brexafemme is a novel oral antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as vaginal yeast infection. Its mechanism of action, glucan synthase inhibition, is fungicidal against Candida species, meaning it kills fungal cells.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
BREXAFEMME is a novel first-in-class fungicidal triterpenoid antifungal, designed to kill the yeast causing the infection, including azole-resistant strains. The one-day oral medication represents the first new antifungal class approved by the FDA in more than 20 years.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2021
Details:
Company announced that the EMA has granted orphan medicinal product designation to ibrexafungerp with the vision to build a global antifungal franchise for community and hospital infections by leveraging the versatility and potency antifungal agent to benefit patients.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2021
Details:
The global Phase 3 multi-center, prospective, randomized, double-blind study of two treatment regimens will evaluate oral ibrexafungerp as a step-down treatment in patients suffering from invasive candidiasis (IC) compared to oral fluconazole.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: FDA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 06, 2021
Details:
Ibrexafungerp is a novel, broad-spectrum antifungal with the potential to become an essential therapy in the treatment of multiple serious fungal infections, including invasive candidiasis, invasive aspergillosis, and refractory invasive fungal infections.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2021
Details:
BREXAFEMME® (Ibrexafungerp) demonstrated sustained clinical effect at Day-25 follow-up with 73.9% of treated patients achieving a complete resolution of signs and symptoms. The Phase 3 VANISH clinical trial program (VANISH-303 and VANISH-306) supported approval of BREXAFEMME.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2021
Details:
The NDA was supported by positive results from two Phase 3, randomized, double-blind, placebo-controlled, multi-center studies (VANISH-303 and VANISH-306), in which oral ibrexafungerp demonstrated efficacy and a favorable tolerability profile in women with VVC.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021
Details:
Ibrexafungerp is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids for treatment of mucormycosis.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
Of the 74 patients treated with oral ibrexafungerp 62.1% showed complete or partial response, 24.3% achieved stable disease, 6.8% showed progressive disease, and 5.4% were indeterminate. One patient died due to an unrelated cause.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2021
Details:
Ibrexafungerp (pronounced eye-BREX-ah-FUN-jerp) is antifungal agent and first representative of novel class of structurally-distinct glucan synthase inhibitors, triterpenoids, used for treatment of patients with refractory mucocutaneous and invasive fungal infections.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2021
Details:
BREXAFEMME is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC), or vaginal yeast infections.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
The capital strengthens SCYNEXIS’ balance sheet ahead of the anticipated commercial launch of Brexafemme, expected trade name for ibrexafungerp, an oral antifungal product for the treatment of vaginal yeast infections, which is under regulatory review by the U.S. FDA.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hercules Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing May 14, 2021
Details:
SCYNEXIS presented two posters entitled as "Phase 3 Oral Ibrexafungerp Study in Vulvovaginal Candidiasis (VANISH-303): Outcomes in Non-albicans Candida spp" and "Efficacy and Safety of Oral Ibrexafungerp in the treatment of Vulvovaginal Candidiasis: A Phase 3 Study".
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Brexafemme
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2021
Details:
The posters are titled as: Phase 3 Oral Ibrexafungerp Study in Vulvovaginal Candidiasis: Outcomes in Non-albicans Candida spp and Efficacy and Safety of Oral Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis: A Phase 3 Study.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: SCY-078
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2021
Details:
Under the terms of the agreement, Hansoh will obtain an exclusive license from SCYNEXIS to research, develop and commercialize ibrexafungerp in the Greater China region.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: SCY-078
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hansoh Pharma
Deal Size: $122.0 million Upfront Cash: $10.0 million
Deal Type: Partnership February 17, 2021
Details:
The poster presentations will highlight clinical and preclinical data supporting ibrexafungerp’s potential to combat serious and life-threatening fungal infections.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: SCY-078
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
Based on FDA feedback, the Company believes its regulatory package will be sufficient to support a submission of ibrexafungerp for the treatment of VVC.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: SCY-078
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2020
Details:
Mr. Maffezzoli will lead marketing and commercialization of SCYNEXIS’s lead clinical asset, ibrexafungerp, pending regulatory approval, for the treatment of vulvovaginal candidiasis (VVC), more commonly known as vaginal yeast infection.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
Ibrexafungerp achieved highly statistically significant superiority over placebo for the primary and key secondary study endpoints.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2020
Details:
Preclinical in vitro data showed synergistic activity against Aspergillus isolates from lung transplant recipients.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2020
Details:
SCYNEXIS has completed patient enrollment in its global Phase 3 VANISH-306 study to evaluate the safety and efficacy of oral ibrexafungerp as a treatment for women with vulvovaginal candidiasis (VVC),
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2020
Details:
Results confirm clinical antifungal activity of oral ibrexafungerp in patients with difficult-to-treat, severe, mucocutaneous and invasive fungal infections, including those caused by resistant strains.
Lead Product(s): Ibrexafungerp Citrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
